ALPS Medical Breakthroughs ETF

Frequently Asked Questions About SBIO

What does SBIO invest in?

The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

What is the expense ratio of SBIO?

ALPS Medical Breakthroughs ETF (SBIO) charges an expense ratio of 0.50%. This is the annual fee deducted from fund assets to cover management and operations.

How big is SBIO?

ALPS Medical Breakthroughs ETF (SBIO) manages $234.7M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is SBIO actively managed or an index fund?

SBIO's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was SBIO launched?

ALPS Medical Breakthroughs ETF (SBIO) launched in December 2014 and is managed by ALPS Funds.

How has SBIO performed?

SBIO's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.